Neoadjuvant therapy-induced sarcopenia, reduced OS linked in pancreatic ductal adenocarcinoma

Neoadjuvant therapy-induced sarcopenia in patients who underwent neoadjuvant therapy for pancreatic ductal adenocarcinoma correlated with increased disease recurrence and overall mortality, and reduced overall survival, according to a presentation from Digestive Disease Week.“Patients who have pancreatic cancer are being preferentially treated with chemotherapy and/or radiation before surgery to ensure complete delivery while they are healthy,” Motaz Qadan, MD, PhD, from Massachusetts General Hospital in Boston, told Healio Gastroenterology and Liver Disease. “However, weRead More